<DOC>
	<DOCNO>NCT00555217</DOCNO>
	<brief_summary>Diabetes lead cause end-stage renal disease ( ESRD ) United States . The overall rate ESRD secondary diabetes rise 68 % since 1992 . Medications block renin angiotensin system show decrease progression diabetic nephropathy . The use angiotensin receptor blocker ( ARB ) show decrease risk progression kidney disease two study individual Type 2 diabetes proteinuria . Despite use ARB , incidence renal failure remain high treat group study . The combination angiotensin convert enzyme inhibitor ( ACEI ) ARB lead complete blockade renin angiotensin system . In diabetic kidney disease , combination therapy show decrease proteinuria short-term study . Although encouraging result improvement proteinuria data progression kidney disease use combination ACEI ARB therapy patient diabetes . In addition , could increase risk serious hyperkalemia individual diabetes receive combination ACEI ARB . The investigator therefore propose randomize double blind multi-center clinical trial ass effect combination ACEI ARB patient diabetes proteinuria progression kidney disease .</brief_summary>
	<brief_title>VA NEPHRON-D : Diabetes iN Nephropathy Study</brief_title>
	<detailed_description>Primary Hypothesis : To evaluate combination angiotensin convert enzyme inhibitor ( ACEI ) angiotensin receptor blocker ( ARB ) vs. standard treatment angiotensin receptor blocker progression kidney disease individual Type 2 diabetes overt nephropathy . The primary outcome composite endpoint reduction estimate GFR 30 ml/min/1.73m*m individual estimate baseline GFR great equal 60 ml/min/1.73m*m ; reduction estimate GFR great 50 % individual estimate baseline GFR le 60 mL/min/1.73m*m ; progression end-stage renal disease ( define need dialysis , renal transplant eGFR le 15 ml/min/1.73m*m ) death . Secondary outcome : renal composite endpoint , define ; reduction estimate GFR 50 % ( individual baseline estimate GFR le 60 ml/min/1.73m*m ) ; reduction estimate GFR 30 ml/min/1.73m*m ( individual baseline estimate GFR great equal 60 ml/min/1.73m*m ) progression end-stage renal disease ( define need dialysis , renal transplant eGFR le 15 ml/min/1.73m*m ) . Tertiary outcome cardiovascular event ( cardiovascular mortality , myocardial infarction , cerebrovascular accident , admission heart failure ) , change albuminuria 12 month decline slope kidney function . Study Abstract : The study multi-center , prospective , randomize , parallel group trial test efficacy combination angiotensin convert enzyme inhibitor ( ACEI ) angiotension receptor blocker ( ARB ) vs. standard treatment angiotension receptor blocker combine end-point . The primary outcome composite endpoint reduction estimate GFR 30 ml/min/1.73m*m individual estimate GFR great equal 60 ml/min/1.73m*m ; reduction estimate GFR great 50 % individual estimate GFR le 60 ml/min/1.73m*m ; progression end-stage renal disease ( define need dialysis , renal transplant en eGFR le 15 ml/min/1.73m*m ) death . The study population individual type 2 diabetes overt nephropathy . Eligible subject consent participate randomize either combination therapy arm mono therapy arm . The randomization stratify site within site baseline albuminuria ( &lt; 1 vs. great equal 1 gram/gram creatinine ) eGFR ( &lt; 60 vs. great equal 60 ml/min/1.73m*m ) . All participant receive open label therapy losartan , ARB , standard care . Patients treat ACEI ARB initiate losartan ; patient treat ACEI ARB losartan ( study ARB ) convert losartan ( study ARB ) dose titrate 100 mg/day . Individuals tolerate ARB 100mg/day criterion randomize 1:1 ratio addition blind lisinopril ( study ACEI ) placebo . The medication ( lisinopril placebo ) titrate initial dose 10 mg/day target dose 40 mg/day . After adjustment dose , serum chemistry evaluate kidney function potassium level . Subjects enrol period 4.25 year maximum length follow-up 6.25 year . The plan study duration 6.25 year 4.25 year accrual 6.25 year follow-up enrol patient . The intervention stop November 7 , 2012 safety concern interim analysis . Patients still passively follow-up without intervention .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Enzyme Inhibitors</mesh_term>
	<mesh_term>Lisinopril</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Type 2 diabetes Albuminuria &gt; 300mg/gram creatinine Stage 2 3 CKD ( eGFR 30 &lt; 90 mg/min/1.73m*2 ) Able give informed consent Telephone contact available History intolerance ACEI ARB Serum potassium level &gt; 5.5 meq/L Receiving sodium polystyrene sulfonate ( Kayexalate ) Pregnancy , breast feeding , plan become pregnant sexually active use birth control Renal transplant recipient Suspected nondiabetic kidney disease Inability discontinue current use ACEI/ARB combination Current use Lithium Severe ( endstage ) comorbid disease Prisoner Age &lt; 18 Estimated glomerular filtration rate ( GFR ) &lt; 30 &gt; =90 ml/min/1.73m*m HbA1c &gt; 10.5 % Patient refusal Participation concurrent interventional study Blood pressure &gt; 180/95 Unwilling stop proscribed medication enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>kidney disease</keyword>
	<keyword>nephropathy</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>hyperkalemia</keyword>
	<keyword>acute kidney injury</keyword>
</DOC>